New Drug Introduction: Entresto™ / sacubitril & valsartan
Pharmacology
Manufacturer
Approval date
Indications
Contraindications
Black Box Warnings
Warnings &
Precautions
Pregnancy/Lactation
Pharmacokinetics –
sacubitril
Pharmacokinetics –
valsartan
Drug interactions –
Precipitant/Object
Adverse Effects
(Entresto) [enalapril]
Monitoring Efficacy
Dosing – initial
Dosing – target
Dosing – Max
Renal Adjustment
Hepatic Adjustment
Sacubitril is a prodrug metabolized to the active drug, LBQ657, which
inhibits neprilysin, a neutral endopeptidase, which increases levels of
natriuretic peptides. Valsartan blocks the angiotensin II type-1 receptor.
Novartis Pharmaceuticals Corporation
July 7 2015
Indicated to reduce the risk of cardiovascular death and hospitalization for
heart failure in patients with chronic heart failure (NYHA Class II-IV) and
reduced ejection fraction
Hypersensitivity to any component
History of angioedema related to previous ACE-I or ARB therapy
Concomitant use with ACE inhibitors
Concomitant use with aliskiren in patients with diabetes
Fetal Toxicity
Observe for signs and symptoms of angioedema and hypotension
Monitor renal function and potassium in susceptible patients
Pregnancy – Discontinue as soon as pregnancy is detected
Lactation – not recommended
A – time to peak, plasma: 0.5 hrs; time to peak of metabolite: 2 hrs
D – Protein binding – 94-97%; Vd: 103 L
M – Metabolized by esterases to active metabolite. Major metabolite is not
metabolized.
E – T1/2 sacubitril: 1.4 hrs; T1/2 metabolite: 11.5 hrs
A – bioavailability higher than other formulations
26 mg ~ 40 mg
51 mg ~ 80 mg
103 mg ~ 160 mg
OATP1B1 and OATP1B3 substrates
ACE-I – increased risk of angioedema
Aliskiren – dual RAAS blockade
Potassium-sparing diuretics, ACE-I – increased risk of hyperkalemia
Lithium – increased Lithium concentrations
NSAID – decreased renal function
Hypotension (18) [12]
Hyperkalemia (12) [14]
Dizziness (6) [5]
Impaired renal function (6) [5]
Cough (9) [13]
Angioedema (0.5%) [0.2%]
Blood pressure, S/Sx of Heart Failure
If previous ACE-I or ARB – 49/51 mg bid
If no ACE-I or ARB – 24/26 mg bid
Titrate after 2-4 weeks to 97/103 mg as tolerated by patient
97/103 mg bid
Mild-to-moderate – no dose adjustment
Severe – 24/26 mg bid starting dose; titrate as patient tolerates
Mild – no adjustment
Moderate (Child-Pugh B classification) – 24/26 mg bid; titrate as tolerated
Severe impairment – not recommended
Cost: Source: NY Times – Accessed 08/21/15
Dose(s)
Brand – Generic
49/51 mg
Entresto™ – sacubitril & valsartan
$ (year)
~$4,500
Summary
Entresto™, sacubitril/valsartan, is a novel combination agent that lowers blood pressure and
reduces the risk of cardiovascular death and hospitalization by inhibiting neprilysin and
angiotensin II type-1 receptor, indicated for patients with chronic heart failure (NYHA Class II-IV)
and reduced ejection fraction.
Black box warning for fetal toxicity.
Avoid use in combination with an ACE-I or in patients with a history of angioedema.
Interactions include OATP substrates (lithium), RAAS agents, NSAIDs, and ACE-I.
Blood pressure should be monitored, as hypotension is the most common side effect of
sacubitril/valsartan.
References:
1. Entresto™ [sacubitril and valsartan] package insert. Novartis Pharmaceutical Corporation. July
2015.
2. McMurray, J, et al. PARADIGM-HF Study. New England Journal of Medicine.
2014;371;11:993-1004.
3. Pollack, A. The New York Times Website. F.D.A. Approves Heart Drug Entresto Said to Cut
Death Risk by 20%. http://www.nytimes.com/2015/07/08/business/international/fda-approvesheart-drug-entresto-after-promising-trial-results.html. Published July 7, 2015. Accessed August
21, 2015.
Date Prepared: August 24, 2015
Editor:
Peter G. Koval, Pharm.D., BCPS
Author:
Leslie Perry, Pharm.D. Candidate, UNC Eshelman School of Pharmacy